Expression of HIF-1α and markers of angiogenesis are not significantly different in triple negative breast cancer compared to other breast cancer molecular subtypes: Implications for future therapy Academic Article uri icon

Overview

MeSH Major

  • Biomarkers, Tumor
  • Breast Neoplasms
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Neovascularization, Pathologic

abstract

  • A proportion of TNBC express HIF-1α but not in a significantly different manner from other breast cancer subtypes. The potential of anti-HIF-1α targeted therapy is therefore not a candidate for exclusive use in TNBC, but should be considered in all breast cancers, especially in the setting of clinically aggressive or refractory disease.

publication date

  • June 5, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4457831

Digital Object Identifier (DOI)

  • 10.1371/journal.pone.0129356

PubMed ID

  • 26046764

Additional Document Info

start page

  • e0129356

volume

  • 10

number

  • 6